Bristol-Myers Squibb Company logo

Bristol-Myers Squibb Company(BMY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
3-STAR RATING
WEAK BUY
BUY for 5 days
PROFIT SINCE LAST BUY
-6.56% ▼
LAST CLOSE
$58.8
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BMY

11/20/2026: BMY (3-star) is a WEAK-BUY. BUY for 5 days. Simulated Profits (-6.56%). Updated daily EoD!

Bristol-Myers Squibb Company is a major global biopharmaceutical enterprise specializing in oncology, immunology, cardiovascular, and neuroscience therapies. The company's primary strength lies in its fast-expanding growth portfolio—featuring blockbusters like Opdivo, Camzyos, and Breyanzi—which successfully offsets declines in legacy products. Its core investment appeal centers on steady cash flow generation, a reliable dividend history, and an innovative pipeline targeting specialty care. However, the company faces substantial risks from impending patent cliffs on older drugs and intense biopharmaceutical competition. The stock suits value and dividend-focused investors seeking steady income while monitoring clinical trial catalysts and pipeline execution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile the growth portfolio expands rapidly, legacy patent expirations temper overall corporate top-line expansion speed.
Momentum investorStrong fit while signal remains positiveMomentum appeal depends closely on positive clinical trial readouts and commercial beats from new product launches.
Value investorStrong fitThe stock often trades at a modest valuation multiple relative to earnings, supported by solid cash flow generation.
Dividend investorStrong fitA consistent history of dividend growth and a high yield make it attractive for income-focused portfolios.
Low-risk investorMixed fitSteady pharmaceutical demand provides defensive characteristics, though binary clinical trial and patent risks introduce volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumBiopharmaceutical stocks can experience short-term swings driven by regulatory decisions and clinical data readouts.
Valuation riskLow / noneReasonable earnings multiples limit excessive valuation downside compared to high-flying growth sectors.
Competition risk (name the main competitor theme, e.g. AI competition)Medium / highIntense rivalry from major competitors like Merck and Pfizer threatens market share across core therapeutic categories.
Business qualityStrongThe company maintains a high-quality global franchise with entrenched scientific capabilities and strong operating margins.
Dividend incomeLowThe dividend is well-supported by stable cash flows and an established track record of consecutive annual raises.
Execution riskMedium / highSuccessfully replacing declining legacy revenues with pipeline blockbusters is critical for long-term stability.

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 120.19B USD
Price to earnings Ratio 13.04
1Y Target Price 65.25
Price to earnings Ratio 13.04
1Y Target Price 65.25
Volume (30-day avg) 11.5M shares
Beta 0.19
52 Weeks Range 45.55 - 67.94
Updated Date 11/21/2026
52 Weeks Range 45.55 - 67.94
Updated Date 11/21/2026
Dividends yield (FY) 4.32%
Basic EPS (TTM) 4.51

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Drug Manufacturers - General

BUY participation
90.0%
Active BUY / eligible
9 / 10
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit 23.3%
Avg. Invested days 41
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BMY receives a 4-star rating, supported by strong unit economics, solid company fundamentals, solid quantitative characteristics, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
BMY has solid overall fundamentals (4 stars), with solid financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+178.8%) and strong cash generation (FCF margin 26.7%) are partially offset by slightly negative revenue growth (-0.2%), very low insider ownership of 0.10%.

Financial Health Rating

★★★★★
BMY's financial health is supported by strong cash strength, including free-cash-flow generation of $12.8B (26.7% of revenue). Liquidity is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is BMY's strongest growth driver at +178.8% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (-0.2%, slightly negative) and free-cash-flow growth (-7.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 85.4% and approximately 99.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.10%, which materially reduces the ownership score.

Top 5 Institutional Investors

BlackRock Inc 8.82%
Vanguard Capital Management, LLC 6.52%
State Street Corp 5.01%
JPMorgan Chase & Co 3.51%
Charles Schwab Investment Management Inc 3.31%

Unit Economics (Per $1K Revenue)

★★★★★
BMY generates approximately $711 of gross profit, $285 of operating income, and $267 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins and strong cash conversion support the rating, although capital efficiency remains solid.

Economic Dimensions

★★★★★
Effective Tax Rate: 24.36%

Quantitative Style Profile

★★★★★
BMY has a high-quality, large-cap, liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLow VolatilityLarge / Mega Cap StabilityHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Oncology and Immuno-OncologyGlobal sales of flagship cancer therapies including Opdivo, Opdualag, and cellular therapies like Breyanzi.This is the primary growth engine and largest revenue pillar for the company.
Cardiovascular and Specialty CareSales from blockbuster blood thinner Eliquis, heart medication Camzyos, and hematology product Reblozyl.Provides massive baseline cash flow despite looming patent challenges on older blockbusters.
Geographic MarketsCommercial operations spanning the United States, Europe, and international markets.The United States remains the largest revenue contributor, supplemented by a diversified global footprint.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When Before Market
Estimate 1.21
Actual 1.35

Profitability

Profit Margin 18.47%
Operating Margin (TTM) 32.37%

Management Effectiveness

Return on Assets (TTM) 10.9%
Return on Equity (TTM) 44.01%

Valuation

Trailing PE 13.04
Forward PE 8.87
Enterprise Value 152.42B
Price to Sales(TTM) 2.4
Enterprise Value 152.42B
Price to Sales(TTM) 2.4
Enterprise Value to Revenue 3.05
Enterprise Value to EBITDA 9.66
Shares Outstanding 2.04B
Shares Floating 2.04B
Shares Outstanding 2.04B
Shares Floating 2.04B
Percent Insiders 0.1
Percent Institutions 85.44

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.